On Friday, the fledgling field of psychedelic medicine suffered a major setback. The FDA declined to approve MDMA-assisted therapy for PTSD, instead asking the drugmaker Lykos Therapeutics to conduct ...
Quality evidence is needed to support a new Medicare Part D medication therapy management (MTM) program performance measure, prompting a scoping review on MTM services and associated outcomes.
Thrombolytic therapy defines a group of medications that can dissolve blood clots. Healthcare professionals may administer them to treat a medical emergency, such as a heart attack or stroke. The ...
Drugmaker Lykos Therapeutics announced on Aug. 9, 2024, that the Food and Drug Administration declined to approve the company’s application for the use of MDMA-assisted therapy in the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results